Phase 3
N=109
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
Pulmonary Embolism
Bottom Line
View on ClinicalTrials.gov: NCT04248868 ↗Enrolled (actual)
109
Serious AEs
6.4%
Results posted
Apr 2023
Primary outcome: Primary: Efficacy: RV/LV Ratio Difference — 1.66; 1.10; -0.56 RV/LV Ratio
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- The Bashir™ Endovascular Catheter (Device); r-tPA (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Thrombolex, Inc.
- Primary completion
- Jun 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Efficacy: RV/LV Ratio Difference |
1.66; 1.10; -0.56 | — |
| PRIMARY Safety: Major Bleeding |
1 | — |
Summary
To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using low dose r-tPA for the treatment of acute submassive pulmonary embolism.
Eligibility Criteria
Inclusion Criteria
- Willing and able to provide informed consent;
- Age 18 to ≤ 75 years of age;
- PE symptom duration ≤ 14 days.
- Filling defect in at least one main or lobar pulmonary artery as determined by contrast enhanced chest CT (CTA);
- RV/LV diameter ratio ≥ 0.9 by CTA as determined by the investigative site;
- Willing and able to comply with all study procedures and follow-up.
Exclusion Criteria
- CVA or TIA within one (1) year;
- Head trauma, active intracranial, or intraspinal disease ≤ one (1) year prior to inclusion in the study;
- Active bleeding from a major organ within one (1) month prior to inclusion in the study;
- Intracranial condition(s) that may increase the risk of bleeding (e.g., neoplasms, arteriovenous malformations, or aneurysms);
- Patients with bleeding diatheses;
- Hematocrit 1.5 if currently on warfarin (Coumadin®);
- aPTT > 50 seconds in the absence of anticoagulants;
- Major surgery ≤ 14 days prior to inclusion in the study;
- Serum creatinine > 2.0mg/dL;
- Clinician deems high-risk for catastrophic bleeding;
- History of heparin-induced thrombocytopenia (HIT Syndrome);
- Pregnancy;
- SBP 15 minutes within two (2) hours prior to BEC procedure and is not resolved with IV fluids;
- Any vasopressor support;
- Cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (CPR) during this hospitalization at treating institution and/or referring institution;
- Evidence of irreversible neurological compromise;
- Life expectancy 45kg/m2;
- Absolute contraindication to anticoagulation;
- Uncontrolled hypertension defined as SBP > 175mmHg and / or DBP > 110mmHg with pharmacotherapy within two (2) hours prior to inclusion in the study;
- Currently participating in another study;
- Any arterial line placement;
- Current positive COVID diagnosis, or ≤ 8 weeks negative of COVID, or > 8 weeks from positive COVID test and with current symptoms, or current active viral pneumonia on chest CT scan;
- In the opinion of the investigator, the subject is not a suitable candidate for the study.
Data sourced from ClinicalTrials.gov (NCT04248868). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.